Nova MSC Bhd.
MMYX:NOVAMSC0.05
MYR
+0.01
(+11.11%)
ISIN
MYQ0026OO003
Return %
Stock
S&P 500
1Y
-23.08
14.20
3Y
-52.38
81.12
5Y
-56.52
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Full Time Employees
- 112
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Kuala Lumpur Malaysia
- IPO Date
- Jul 21, 2003
- Website
- nova-hub.com
- Similar Companies
- Business
- Nova MSC Berhad is an investment holding and information technology company that provides industry-focused digital transformation solutions, specialized enterprise software, artificial intelligence diagnostics, and robotics across the healthcare, government, and commercial sectors. Founded in 2002 and headquartered in Kuala Lumpur, Malaysia, the company operates across Malaysia, Singapore, Brunei, Indonesia, Hong Kong, the Maldives, and the Middle East through its key operating subsidiaries, including novaCITYNETS Pte Ltd, novaHEALTH Pte Ltd, EyRIS Pte Ltd, and Dex-Lab Pte Ltd. The company provides a comprehensive portfolio of proprietary software, hardware, and engineering services, comprising Pavo, an electronic document submission, process workflow, and collaboration platform for government authorities; Fornax, an automated electronic plan-checking (ePlanCheck) system utilizing building information modeling and 2D/3D computer-aided design data for regulatory compliance and approval; the Enterprise Registry and Archival (ERA) platform for municipal and government records management; Vesalius, an enterprise web-based hospital information system integrating clinical, operational, administrative, and financial workflows; Avicenna, a cloud-native clinic management and electronic medical records platform for multi-specialty centers and outpatient clinics; SELENA+, an artificial intelligence and deep-learning diagnostic software platform for automated retinal image analysis to detect diabetic retinopathy, glaucoma suspect, and age-related macular degeneration; DEXIE and DAISY, conversational and social humanoid assistive robots designed for cognitive stimulation and companion care in eldercare facilities; and automated laboratory management and sample processing engineering solutions; supplemented by software research and development, systems architecture, custom application development, systems integration, project management, IT infrastructure consultancy, and multi-year technical maintenance and support services. Recent operational and corporate developments include securing a 35.4 million Malaysian Ringgit contract via novaCITYNETS for the supply, implementation, and maintenance of an automated administration, labelling, and sample processing system; awarding of a 7.13 million Malaysian Ringgit contract through EyRIS to implement Brunei Darussalam's national diabetic retinopathy screening program powered by the SELENA+ AI platform; receiving a 7.0 million Malaysian Ringgit system operations and maintenance extension contract from Singapore's Land Transport Authority; executing strategic distribution and tele-optometry partnerships to expand AI diagnostic screening across retail optical chains and clinical networks in Southeast Asia; initiating preparatory steps and appointing financial advisers for the proposed initial public offering and listing of its healthcare robotics subsidiary Dex-Lab on the Singapore Exchange Catalist board; and realigning executive leadership under Executive Chairman Sunny Loh to accelerate group-wide restructuring and commercialization across its artificial intelligence and digital healthcare units.